Intensity Therapeutics Inc
Company Profile
Business description
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
Contact
1 Enterprise Drive
Suite 430
SheltonCT06484-4779
USAT: +1 203 221-7381
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16
Stocks News & Analysis
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
stocks
Chart of the Week: Software selloff creates opportunity for these two stocks
stocks
Market is misinterpreting AI impact on cheap ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,408.70 | 27.40 | -0.29% |
| CAC 40 | 8,620.93 | 61.86 | 0.72% |
| DAX 40 | 25,289.02 | 113.08 | 0.45% |
| Dow JONES (US) | 49,466.47 | 15.68 | -0.03% |
| FTSE 100 | 10,846.70 | 40.29 | 0.37% |
| HKSE | 26,381.02 | 384.70 | -1.44% |
| NASDAQ | 22,784.47 | 367.61 | -1.59% |
| Nikkei 225 | 58,753.39 | 170.27 | 0.29% |
| NZX 50 Index | 13,670.71 | 145.13 | 1.07% |
| S&P 500 | 6,889.89 | 56.24 | -0.81% |
| S&P/ASX 200 | 9,175.30 | 27.60 | -0.30% |
| SSE Composite Index | 4,146.63 | 0.60 | -0.01% |